Highlights

  • First patient dosed in Phase 2a clinical trial of ARG-007 for ischaemic stroke neuroprotection
  • ARG-007 is a novel peptide derived from humanin with a unique neuroprotective mechanism of action
  • Stroke represents an enormous unmet medical need with no approved neuroprotective agent
  • Phase 2a trial evaluating safety, pharmacokinetics, and early signs of neuroprotective activity

Argenica Therapeutics Limited (ASX:AGN), trading at A$0.15 as at 30 October 2026, has achieved a landmark clinical milestone by dosing the first patient in its Phase 2a clinical trial of ARG-007, its lead neuroprotective peptide candidate for the treatment of ischaemic stroke, marking the first progression of a novel stroke neuroprotection drug candidate into a Phase 2 human clinical trial in a disease area that has historically been characterised by a long series of clinical failures and where no approved neuroprotective agent yet exists.

ARG-007: A Novel Stroke Neuroprotection Approach

ARG-007 is a peptide derived from humanin, a naturally occurring peptide encoded in the mitochondrial genome that has been shown to have potent cytoprotective and neuroprotective properties in preclinical models of cellular stress and neuronal injury. Argenica's scientific team has developed ARG-007 as an optimised humanin analogue with improved potency, stability, and brain penetration characteristics relative to the native humanin peptide. The mechanism of action of ARG-007 involves protection of neurons from the cascade of cellular injury events that occur after ischaemic stroke, including excitotoxicity, oxidative stress, and mitochondrial dysfunction. By targeting the mitochondrial pathway of neuronal cell death, ARG-007 has a mechanistically distinct approach from the many neuroprotective candidates that have failed in clinical trials targeting the NMDA receptor and other pathways.

Stroke: An Enormous and Unmet Clinical Need

Ischaemic stroke is one of the leading causes of death and long-term disability globally, occurring when a blood clot blocks an artery supplying blood to the brain, causing neurons in the affected area to die from oxygen deprivation. Current treatment options for ischaemic stroke are limited to reperfusion therapies – clot-busting thrombolysis with tPA and mechanical thrombectomy to physically remove the clot – which are effective if administered within narrow time windows but do not address the subsequent wave of neuronal injury that occurs even after blood flow is restored. Despite decades of research and dozens of clinical trials, no neuroprotective agent has ever achieved regulatory approval for ischaemic stroke. ARG-007 represents one of a small number of mechanistically innovative candidates attempting to break this pattern of clinical failures.

Phase 2a Trial Design: Safety and Early Efficacy Signals

Argenica's Phase 2a clinical trial of ARG-007 is a dose-escalation study primarily designed to evaluate the safety and tolerability of ARG-007 when administered to ischaemic stroke patients in the clinical setting, as well as the pharmacokinetic profile of ARG-007 in the acute stroke patient population. The trial is being conducted at leading Australian stroke centres with experienced stroke neurology teams. Secondary objectives include exploratory assessment of neuroprotection biomarkers and clinical outcome measures that may provide early signals of ARG-007's activity in patients. A successful Phase 2a – demonstrating a clean safety profile and preliminary evidence of neuroprotective activity – would support progression to a larger, powered Phase 2b efficacy trial.

Regulatory Strategy and Clinical Development Plan

Argenica is developing ARG-007 under the Australian regulatory framework initially, with the Phase 2a trial conducted under the TGA's Clinical Trial Notification pathway. The Company's longer-term regulatory strategy involves engagement with the US FDA to understand the pathway toward IND (Investigational New Drug) application and eventual Phase 3 development in the United States, which is the primary commercial market for novel stroke treatments. Argenica has been building its intellectual property portfolio around the ARG-007 compound and its application in stroke and other neurological conditions.